Thanks Nick. great info. We need canned responses like this so we can not have to repeatedly answer the same questions asked by the same people. Just give them a link
Also, if ATL or someone else comes up with a comparison table for the new secondary endpoint rGBM like he did for the new Primary endpoint nGBM which is very useful, that would be immensely valuable.
$NWBO: The new #DCVax Phase 3 trial Primary Endpoint is: "compare overall survival between patients randomized to DCVax-L & control patients from comparable, contemporaneous trials who received SOC, in patients with newly diagnosed Glioblastoma". I updated my comparison Table: pic.twitter.com/bzgpUrgN51
I think alphapuppy did a beautiful analysis on the new third and fourth endpoints which were the original Primary and Secondary endpoints that he was predicting a success.